Skip to Main Content
International Institute for Nanotechnology
Kabiller Prize • News • Events • Employment
  • About
    • Message from the Director
    • Partners
      • Centers & Institutes
      • Research Initiatives
      • Laboratories
      • Government Agencies
      • Academic
      • Industrial
    • Facilities
  • People
    • Executive Council
    • Steering Committee
    • Affiliated Faculty
      • Weinberg College of Arts & Sciences
      • Kellogg School of Management
      • Feinberg School of Medicine
      • McCormick School of Engineering & Applied Science
    • Administration
  • Research
    • NanoMedicine
      • Northwestern University Center of Cancer Nanotechnology Excellence (CCNE)
        • NU-CCNE Project 1
        • NU-CCNE Project 2
        • NU-CCNE Project 3
        • NU-CCNE Oligonucleotide Synthesis and Nanoconstructs Core
      • NTU-Northwestern Institute for Nanomedicine (NNIN)
        • NNIN Executive Committee
    • NanoOncology
      • Ronald and JoAnne Willens Center for Nano Oncology
        • Willens Center Project 1
        • Willens Center Project 2
        • Willens Center Project 3
        • Willens Center Project 4
        • Willens Center Project 5
    • NanoEnvironment
      • Nanotechnology for Universal Clean Air & Water Security (NU-CAWS)
        • NU-CAWS Affiliated Faculty
        • NU-CAWS Research Highlights
    • NanoEnergy
    • NanoMaterials
      • Center of Excellence for Advanced Bioprogrammable Nanomaterials (C-ABN)
        • Thrust 1 - Materials & Methods Development
        • Thrust 2 - Functional Substrates
        • Thrust 3 - Advanced Biosensing
    • Molecular Electronics
    • Security & Defense
  • Education
    • Ryan Graduate Fellowships
    • IIN Postdoctoral Fellowships
    • Frontiers in Nanotechnology Seminar Series
    • Research Experience for Undergraduates (REU)
    • All Scout Nano Day
    • Nano Boot Camp for Clinicians
    • Nanotechnology Town Hall Meetings
  • Industry
    • Nanotechnology Corporate Partners (NCP) Program
    • Small Business Partnership
  • Giving
  • Kabiller Prize
    • Overview
    • Nomination Process
    • About David Kabiller
    • Kabiller Prize Winners
      • 2019 Chad Mirkin
      • 2017 Robert Langer
      • 2015 Joe DeSimone
    • Kabiller Young Investigator Award Winners
      • 2019 Molly Stevens
      • 2017 Liangfang Zhang
      • 2015 Warren Chan
  • News
  • Events
    • 2020 IIN Virtual Symposium
    • Frontiers in Nanotechnology Seminar Series
    • Nano Boot Camp for Clinicians
    • Nanotechnology Town Hall Meetings
  • Employment
    • Assistant, Associate or Full Professor of Nanotechnology
close
‹ back to news & updates

Engineering drug delivery vehicles to control clearance by the immune system

Posted by Mark Heiden, Posted in News, Research
Share:

Findings about how the chemistry of nanoparticles can specify their interactions with proteins in blood leads to new strategies for controlling the delivery of therapeutics

by Brian Sandalow

The development of new medications brings numerous challenges. One key obstacle is that cells of the immune system will rapidly remove drugs and nanoparticles from circulation, resulting in less of the drug getting to the intended therapeutic target and generating unwanted side effects.

Recent work from a group of Northwestern Engineering researchers could help solve that issue.

A team led by Evan Scott, the Kay Davis Professor of Biomedical Engineering and Microbiology-Immunology and an affiliated faculty member of the International Institute for Nanotechnology, and his biomedical engineering PhD student Michael Vincent demonstrated that the extent to which a common protein found in blood unravels on the surfaces of drug delivery vehicles will determine how such nanocarriers distribute throughout the body. Engineering drug nanocarriers to either stabilize or unravel albumin — a protein that helps maintain osmotic pressure in the bloodstream — can tune the nanocarrier’s cellular interactions and circulation time. Leveraging these relationships may improve drug specificity, decrease dosage, and minimize adverse outcomes for patients receiving treatments for a variety of diseases, particularly those requiring intravenous drug administration.

Evan Scott

Evan Scott

“Our findings can be used to develop drug delivery vehicles that selectively engage or evade the immune system in specific ways and control their circulation time in blood,” Scott said.

The research was presented in the paper “Surface Chemistry-mediated Modulation of Adsorbed Albumin Folding State Specifies Nanocarrier Clearance by Distinct Macrophage Subsets” published January 28 in Nature Communications.

When nanocarriers are injected into the blood, proteins will stick to their surfaces and change their structure and shape, which alerts the immune system of the presence of a foreign material. It is well established that nanocarriers first become coated with the most abundant blood protein, serum albumin, but this is usually considered to be an inert interaction. Scott’s research built on that knowledge, finding that this inertness is highly dependent on the chemistry of the nanocarrier.

Scott and his team showed that the nanocarrier surface chemistry can be engineered to modulate the structure of albumin as it denatures. Controlling the structure of denatured albumin that coats nanocarrier surfaces determines how the nanocarrier interacts with the innate immune system at the molecular level, and how quickly it is removed from blood. Nanocarrier surface chemistries that disrupt albumin’s structure were rapidly cleared by immune cells called macrophages, and this clearance event was found to be mediated by interactions with scavenger receptors.

In contrast, surface chemistries that stabilize albumin were shown to evade this receptor-mediated clearance mechanism and prolonged nanocarrier circulation in blood.

“We found that surfaces modified with phosphate groups are able to maintain albumin structure and avoid its denaturation,” Scott said. “This presents a novel method of controlling the clearance and biodistribution of nanocarriers, and thus their delivered therapeutics.”

Previously, it was thought that albumin coatings only had a stealth effect that enabled drug delivery vehicles to circulate in blood for a longer period of time. This became the conventional thinking, Scott said, even though no one had investigated if there were conditions where albumin coatings actually accelerate nanocarrier clearance. Scott and Vincent demonstrated that the folding state of albumin at the nanocarrier surface is indeed a controllable surface property that can be exploited to meet diverse challenges in drug delivery.

Read at McCormick School of Engineering

No Comments


No comments yet.

Leave a Reply Cancel reply

* Get an image next to your comment by visiting Gravatar.com and uploading a profile photo that links to your email address.

    Categories

    • Awards and Honors
    • Multimedia
    • Nanoscape Newsletter
    • Nanotechnology at Northwestern
    • News
    • Research
    My Tweets

    For Journalists

    NORTHWESTERN MEDIA CONTACT

    Megan Fellman
    Science and Engineering Editor
    Phone: 847-491-3115
    Email: Megan Fellman

    IIN MEDIA CONTACT

    Kathleen Cook
    Chief of Staff
    Phone: 847-467-5335
    Email: Kathleen Cook

Signup For Our Newsletter

Sign up for our newsletter to receive information on events, news, and articles.

More Info
  • Privacy Policy
  • Tech Transfer
  • News & Events
  • Contact Us
  • Sitemap
  • Education
  • About Us
  • Nano101
  • Facilities
  • Partners
Follow Us
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
  • Instagram

Northwestern University

© International Institute for Nanotechnology